CatalpolCAS# 2415-24-9 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 2415-24-9 | SDF | Download SDF |
PubChem ID | 91520 | Appearance | Colorless/white powder |
Formula | C15H22O10 | M.Wt | 362.3 |
Type of Compound | Iridoids | Storage | Desiccate at -20°C |
Synonyms | Catalpinoside | ||
Solubility | DMSO : ≥ 30 mg/mL (82.80 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | (2S,3R,4S,5S,6R)-2-[[(1aS,1bS,2S,5aR,6S,6aS)-6-hydroxy-1a-(hydroxymethyl)-2,5a,6,6a-tetrahydro-1bH-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
SMILES | C1=COC(C2C1C(C3C2(O3)CO)O)OC4C(C(C(C(O4)CO)O)O)O | ||
Standard InChIKey | LHDWRKICQLTVDL-PZYDOOQISA-N | ||
Standard InChI | InChI=1S/C15H22O10/c16-3-6-9(19)10(20)11(21)14(23-6)24-13-7-5(1-2-22-13)8(18)12-15(7,4-17)25-12/h1-2,5-14,16-21H,3-4H2/t5-,6-,7-,8+,9-,10+,11-,12+,13+,14+,15-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Catalpol is a kind of enzyme inhibitors, it has been shown to have antioxidation, anti-inflammation, anti-apoptosis and other neuroprotective properties and plays a role in neuroprotection against hypoxic/ischemic injury, AD and PD in both in vivo and in vitro models.Catalpol regulates cholinergic nerve system function through effect on choline acetyl-transferase not M receptor affinity, it has a wide spectrum of targets including Bcl-2 , PI3K, Akt-eNOS, caspase. |
Targets | SOD | TLR | NF-kB | MAPK | IL Receptor | TNF-α | Akt | PI3K | NOS | NO | Bcl-2/Bax | Caspase | ROS |
In vitro | Catalpol protects primary cultured astrocytes from in vitro ischemia-induced damage.[Pubmed: 18337048 ]Int J Dev Neurosci. 2008 May-Jun;26(3-4):309-17.Catalpol, an iridoid glycoside abundant in the roots of Rehmannia glutinosa, has been previously found to prevent the loss of CA1 hippocampal neurons and to reduce working errors in gerbils after ischemia-reperfusion injury. |
In vivo | Protective effect of catalpol on lipopolysaccharide-induced acute lung injury in mice.[Pubmed: 25063711]Int Immunopharmacol. 2014 Dec;23(2):400-6.Catalpol, an iridiod glucoside isolated from Rehmannia glutinosa, has been reported to have anti-inflammatory properties. Although anti-inflammatory activity of Catalpol already reported, its involvement in lung protection has not been reported. Thus, we investigated the role of Catalpol on lipopolysaccharide (LPS)-induced acute lung injury in this study. Catalpol promotes oligodendrocyte survival and oligodendrocyte progenitor differentiation via the Akt signaling pathway in rats with chronic cerebral hypoperfusion.[Pubmed: 24632336]Brain Res. 2014 Apr 29;1560:27-35.Chronic cerebral hypoperfusion is thought to induce white matter lesions (WMLs), which contribute to cognitive impairment. Although inflammation and oligodendrocyte apoptosis are believed to be involved in the pathogenesis of WMLs, effective therapies have not been identified yet. This study investigated whether Catalpol, an iridoid glycoside, can alleviate WMLs by promoting oligodendrocyte survival and oligodendrocyte progenitor differentiation via the Akt signaling pathway in rats with chronic cerebral hypoperfusion. |
Kinase Assay | Catalpol protects mice against renal ischemia/reperfusion injury via suppressing PI3K/Akt-eNOS signaling and inflammation.[Pubmed: 25932134]Int J Clin Exp Med. 2015 Feb 15;8(2):2038-44.Renal ischemia/reperfusion-injury (IRI) is a common disease in clinic, which is also the most common cause of acute kidney failure. Previous investigations has illustrated that Catalpol has neuroprotective, anti-inflammatory, and anti-hepatitis virus effects. This study was designed to investigate the protective effect of Catalpol on renal IRI mice through suppressing phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt)-endothelial nitric oxide synthase (eNOS) and against inflammation, and the possible underlying mechanism. |
Cell Research | Catalpol inhibits apoptosis in hydrogen peroxide-induced cardiac myocytes through a mitochondrial-dependent caspase pathway.[Pubmed: 27166426]Catalpol regulates cholinergic nerve system function through effect on choline acetyl-transferase not M receptor affinity.[Pubmed: 25661372]Biomed Pharmacother. 2015 Feb;69:291-6.To explore the effect of Catalpol on choline acetyl-transferase and M receptor affinity in a PC12 cell model and a rat model induced by beta-amyloid 25-35 (Aβ25-35).
Biosci Rep. 2016 Jun 30;36(3). pii: e00348.Catalpol, an iridoid glucoside, has been reported to inhibit apoptosis of neuron and endothelial cells. In the present study, we investigated the mechanism of Catalpol-mediated cardioprotection. |
Animal Research | Catalpol provides protective effects against cerebral ischaemia/reperfusion injury in gerbils.[Pubmed: 24720795]J Pharm Pharmacol. 2014 Sep;66(9):1265-70.To investigate the protective effect of Catalpol on cerebral ischaemia/reperfusion (CI/R) injury in gerbils and further explore the underlying mechanism.
|
Catalpol Dilution Calculator
Catalpol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7601 mL | 13.8007 mL | 27.6014 mL | 55.2029 mL | 69.0036 mL |
5 mM | 0.552 mL | 2.7601 mL | 5.5203 mL | 11.0406 mL | 13.8007 mL |
10 mM | 0.276 mL | 1.3801 mL | 2.7601 mL | 5.5203 mL | 6.9004 mL |
50 mM | 0.0552 mL | 0.276 mL | 0.552 mL | 1.1041 mL | 1.3801 mL |
100 mM | 0.0276 mL | 0.138 mL | 0.276 mL | 0.552 mL | 0.69 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Catalpol, an iridoid glycoside, has neuroprotective, anti-inflammatory, and anti-hepatitis virus effects. IC50 Value: Target: neuroprotective, anti-inflammatory, and anti-hepatitis virus natural product. In vitro: Catalpol could be encapsulated into composite nanofibers and induce differentiation of hASCs into neural-like cells, which might offer new avenues in nerve regeneration [1]. In vivo: The pharmacokinetics of catalpol in normal and doxorubicin-induced chronic kidney disease rats after oral administration of Rehmannia glutinosa extract was determined, and the extraction recoverie of catalpol was higher than 68.24% [2]. The protective effect of catalpol on renal IRI mice through suppressing phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt)-endothelial nitric oxide synthase (eNOS) and against inflammation, and the possible underlying mechanism [3].
References:
[1]. Zhao M, et al.Comparative pharmacokinetics of catalpol and acteoside in normal and chronic kidney disease rats after oral administration of Rehmannia glutinosa extract. Biomed Chromatogr. 2015 May 29.
[2]. Guo JH, et al.Potential Neurogenesis of Human Adipose-Derived Stem Cells on Electrospun Catalpol-Loaded Composite Nanofibrous Scaffolds. Ann Biomed Eng. 2015 Mar 31.
[3]. Zhu J,Catalpol protects mice against renal ischemia/reperfusion injury via suppressing PI3K/Akt-eNOS signaling and inflammation. Int J Clin Exp Med. 2015 Feb 15;8(2):2038-44.
[4]. Xu Z, et al.Mitochondrial fusion/fission process involved in the improvement of catalpol on high glucose-induced hepatic mitochondrial dysfunction. Acta Biochim Biophys Sin (Shanghai). 2015 Jul 2.
- Isavuconazole
Catalog No.:BCC5515
CAS No.:241479-67-4
- TMS
Catalog No.:BCC7093
CAS No.:24144-92-1
- Khellactone
Catalog No.:BCN6684
CAS No.:24144-61-4
- 2-CMDO
Catalog No.:BCC5671
CAS No.:24140-98-5
- Flupenthixol dihydrochloride
Catalog No.:BCC7851
CAS No.:2413-38-9
- Adaphostin
Catalog No.:BCC3890
CAS No.:241127-58-2
- Sibiricaxanthone B
Catalog No.:BCN2784
CAS No.:241125-81-5
- Sibiricose A6
Catalog No.:BCN2786
CAS No.:241125-75-7
- 6-Isopentenyloxyisobergapten
Catalog No.:BCC8110
CAS No.:24099-29-4
- Digiferruginol
Catalog No.:BCN3450
CAS No.:24094-45-9
- 5-Chlorothiophene-2-carboxylic acid
Catalog No.:BCC8745
CAS No.:24065-33-6
- Isocurcumenol
Catalog No.:BCN3526
CAS No.:24063-71-6
- N-(4-Methylphenyl)-3-oxobutanamide
Catalog No.:BCC9058
CAS No.:2415-85-2
- Febrifugine
Catalog No.:BCN3269
CAS No.:24159-07-7
- Trametenolic acid
Catalog No.:BCN3330
CAS No.:24160-36-9
- Epitulipinolide
Catalog No.:BCN5095
CAS No.:24164-13-4
- Kobusone
Catalog No.:BCN5096
CAS No.:24173-71-5
- Zoniporide dihydrochloride
Catalog No.:BCC7461
CAS No.:241799-10-0
- H-Lys(Boc)-OH
Catalog No.:BCC2982
CAS No.:2418-95-3
- H-Glu(OtBu)-OH
Catalog No.:BCC2933
CAS No.:2419-56-9
- Boc-Glu-OH
Catalog No.:BCC3386
CAS No.:2419-94-5
- Epiyangambin
Catalog No.:BCN7029
CAS No.:24192-64-1
- Bis(4-hydroxy-3-methylphenyl) sulfide
Catalog No.:BCC8885
CAS No.:24197-34-0
- 3,3',4,4'-Benzophenone tetracarboxylic dianhydride
Catalog No.:BCC8593
CAS No.:2421-28-5
Catalpol inhibits apoptosis in hydrogen peroxide-induced cardiac myocytes through a mitochondrial-dependent caspase pathway.[Pubmed:27166426]
Biosci Rep. 2016 Jun 30;36(3). pii: BSR20160132.
Catalpol, an iridoid glucoside, has been reported to inhibit apoptosis of neuron and endothelial cells. In the present study, we investigated the mechanism of Catalpol-mediated cardioprotection. The rat embryonic ventricular myocardial cell line (H9c2) cells were first incubated with Catalpol, and then exposed to hydrogen peroxide (H2O2). The concentration of malondialdehyde (MDA) and the activity of superoxide dismutase (SOD) were all determined by using commercially available kits. Apoptotic cells were assessed by Hoechst 33258 and Annexin V-fluorescein isothiocyanate binding assay. Synthesis of Bcl-2, Bax, cytochrome c and caspase-3 were analysed by real-time semiquantitative reverse transcription-PCR and Western blotting. We observed that apoptosis in H9c2 was associated with increased Bax, cytochrome c, caspase-3, decreased Bcl-2 activity after 24 h of H2O2 exposure. Catalpol pretreatment afforded a marked protection against the above H2O2-mediated cytotoxicity and apoptosis in H9c2 cells. Moreover, the Catalpol pretreatment led to a great reduction in H2O2-induced MDA release and increased SOD. These findings indicated for the first time that pretreatment of H9c2 cells with Catalpol can be against H2O2-induced apoptosis, and the protective effect of Catalpol involves the mitochondrial-dependent caspase pathway and is associated with increased Bcl-2 and decreased Bax expression.
Catalpol protects primary cultured astrocytes from in vitro ischemia-induced damage.[Pubmed:18337048]
Int J Dev Neurosci. 2008 May-Jun;26(3-4):309-17.
Catalpol, an iridoid glycoside abundant in the roots of Rehmannia glutinosa, has been previously found to prevent the loss of CA1 hippocampal neurons and to reduce working errors in gerbils after ischemia-reperfusion injury. In the present study, we investigated the effects of Catalpol on astrocytes in an ischemic model to further characterize its neuroprotective mechanisms. Primary cultured astrocytes exposed to oxygen-glucose deprivation (OGD) followed by reperfusion (adding back oxygen and glucose, OGD-R), were used as an in vitro ischemic model. Treatment of the astrocytes with Catalpol during ischemia-reperfusion increased astrocyte survival significantly in a concentration-dependent manner, as demonstrated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, lactate dehydrogenase (LDH) release and morphological observation. In addition, Catalpol prevented the decrease in mitochondrial membrane potential, inhibited the formation of reactive oxygen species (ROS) and the production of nitric oxide (NO), decreased the level of lipid peroxide and the activity of inducible nitric oxide synthase (iNOS), and elevated the activities of superoxide dismutase (SOD), glutathione peroxidase (GPx) and the content of glutathione (GSH). Our results suggest that Catalpol exerts the most significant cytoprotective effect on astrocytes by suppressing the production of free radicals and elevating antioxidant capacity.
Catalpol promotes oligodendrocyte survival and oligodendrocyte progenitor differentiation via the Akt signaling pathway in rats with chronic cerebral hypoperfusion.[Pubmed:24632336]
Brain Res. 2014 Apr 29;1560:27-35.
Chronic cerebral hypoperfusion is thought to induce white matter lesions (WMLs), which contribute to cognitive impairment. Although inflammation and oligodendrocyte apoptosis are believed to be involved in the pathogenesis of WMLs, effective therapies have not been identified yet. This study investigated whether Catalpol, an iridoid glycoside, can alleviate WMLs by promoting oligodendrocyte survival and oligodendrocyte progenitor differentiation via the Akt signaling pathway in rats with chronic cerebral hypoperfusion. A rat model of chronic cerebral hypoperfusion was created through permanent occlusion of bilateral common carotid arteries. Catalpol (5mg/kg) or saline was intraperitoneally administered daily for 10 days following the operation. On the 30th day after surgery, inflammation, oligodendrocyte apoptosis, and myelin damage in the ischemic white matter were more severe and evident than in the sham control group. Treatment with Catalpol significantly suppressed white matter inflammation and attenuated oligodendrocyte apoptosis and myelin damage. The expression of phosphorylated Akt (p-Akt) and the number of mature oligodendrocytes were also markedly increased by Catalpol treatment, and these effects were reversed by the PI3K inhibitor LY294002. In conclusion, Catalpol attenuates hypoperfusion-induced WMLs by promoting oligodendrocyte survival and oligodendrocyte progenitor differentiation through the Akt signaling pathway. Our results suggest that Catalpol may be a candidate for treating cerebrovascular WMLs.
Catalpol regulates cholinergic nerve system function through effect on choline acetyl-transferase not M receptor affinity.[Pubmed:25661372]
Biomed Pharmacother. 2015 Feb;69:291-6.
OBJECTIVE: To explore the effect of Catalpol on choline acetyl-transferase and M receptor affinity in a PC12 cell model and a rat model induced by beta-amyloid 25-35 (Abeta25-35). METHODS: In PC12 cells, Catalpol (10mumol/l, 100mumol/) or saline was retained in the medium and Abeta25-35 (final concentration 20mumol/l) was added. Choline acetyl-transferase (ChAT) expression was determined by immunocytochemistry, ChAT activity measured by radioenzymatic assay, and M receptor (muscarinic receptor) affinity determined by (3)H-QNB binding test. In Wistar rats, Abeta25-35 was injected intracerebroventricularly to establish AD model. After injection of Abeta25-35, the rats were injected Catalpol at 5 and 10mg/kgd(-1) intraperitoneally for the next 7 days, and saline for the control rats. ChAT expression, ChAT activity and M receptor affinity were tested. Cells and rats all were divided into four groups: Group A (control), Group B (model), Group C (Catalpol low dose), and Group D (Catalpol high dose). RESULTS: Compared with control, both PC12 cell and rat AD models showed decreased expression and activity of ChAT (p<0.01), but M receptor affinity remained the same (p>0.05). Compared with model group, treatment of Catalpol increased expression and activity of ChAT of PC12 cell and rat AD model induced by Abeta25-35, p<0.05 or p<0.01 respectively. But there was no difference of M receptor affinity among the four groups (p>0.05). M receptor affinity remained the same as concentration of Catalpol increased gradually in atropine competition experiments (p>0.05). CONCLUSIONS: Catalpol could regulate the cholinergic nerve system function from its effect on ChAT and may have beneficial effect for treatment of AD, but had no effect on M receptor affinity.
Catalpol provides protective effects against cerebral ischaemia/reperfusion injury in gerbils.[Pubmed:24720795]
J Pharm Pharmacol. 2014 Sep;66(9):1265-70.
OBJECTIVES: To investigate the protective effect of Catalpol on cerebral ischaemia/reperfusion (CI/R) injury in gerbils and further explore the underlying mechanism. METHODS: A gerbil model of CI/R was prepared by bilateral common carotid occlusion for 10 min followed by 6 h reperfusion. Catalpol (5, 10 or 20 mg/kg per day) was injected intraperitoneally for 3 days before the carotid occlusion. Stroke index was measured during the reperfusion. The contents of endogenous neuropeptides, endothelin-1 (ET-1) and calcitonin gene-related peptide in plasma were evaluated by radioimmunoassay. Superoxide dismutase (SOD) and malondialdehyde (MDA) in brain tissue homogenate were also examined. KEY FINDINGS: The results showed that Catalpol significantly improved the stroke index compared with CI/R control group (P < 0.05 or P < 0.01). Catalpol significantly increased the activity of SOD at the doses of 10 and 20 mg/kg (P = 0.05), decreased the brain MDA content and the plasma level of ET-1 at the doses of 10 and 20 mg/kg (P = 0.01). CONCLUSIONS: These data suggested that the efficacy of Catalpol pretreatment on CI/R injury may be attributed to reduction of free radicals and inhibition of lipid peroxidation and ET-1 production.
Protective effect of catalpol on lipopolysaccharide-induced acute lung injury in mice.[Pubmed:25063711]
Int Immunopharmacol. 2014 Dec;23(2):400-6.
Catalpol, an iridiod glucoside isolated from Rehmannia glutinosa, has been reported to have anti-inflammatory properties. Although anti-inflammatory activity of Catalpol already reported, its involvement in lung protection has not been reported. Thus, we investigated the role of Catalpol on lipopolysaccharide (LPS)-induced acute lung injury in this study. Mice acute lung injury model was induced by intranasal instillation of LPS. Catalpol was administrated 1h prior to or after LPS exposure. The severity of pulmonary injury was evaluated 12h after LPS administration. The results showed that Catalpol inhibited lung W/D ratio, myeloperoxidase activity of lung samples, the amounts of inflammatory cells and TNF-alpha, IL-6, IL-4 and IL-1beta in BALF induced by LPS. The production of IL-10 in BALF was up-regulated by Catalpol. In vitro, Catalpol inhibited TNF-alpha, IL-6, IL-4 and IL-1beta production and up-regulated IL-10 expression in LPS-stimulated alveolar macrophages. Moreover, western blot analysis showed that the activation of NF-kappaB and MAPK signaling pathways was inhibited by Catalpol. Furthermore, Catalpol was found to inhibit TLR4 expression induced by LPS. In conclusion, Catalpol potently protected against LPS-induced ALI. The protective effect may attribute to the inhibition of TLR4-mediated NF-kappaB and MAPK signaling pathways.
Catalpol protects mice against renal ischemia/reperfusion injury via suppressing PI3K/Akt-eNOS signaling and inflammation.[Pubmed:25932134]
Int J Clin Exp Med. 2015 Feb 15;8(2):2038-44. eCollection 2015.
Renal ischemia/reperfusion-injury (IRI) is a common disease in clinic, which is also the most common cause of acute kidney failure. Previous investigations has illustrated that Catalpol has neuroprotective, anti-inflammatory, and anti-hepatitis virus effects. This study was designed to investigate the protective effect of Catalpol on renal IRI mice through suppressing phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt)-endothelial nitric oxide synthase (eNOS) and against inflammation, and the possible underlying mechanism. Firstly, we used renal IRI model to analyze blood urea nitrogen and serum creatinine levels in renal IRI mice. Next, real-time PCR and western blotting were used to detect the expression of KIM-1 and the expression of PI3K, Akt and eNOS levels in renal IRI, respectively. In addition, activities of tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and interleukin-10 (IL-10) in renal IRI mice were measured with respective TNF-alpha, IL-1beta, IL-6 and IL-10 ELISA kits. Our results showed that Catalpol clearly reduced blood urea nitrogen, serum creatinine levels and the expression of KIM-1 in renal IRI mice. Meanwhile, we found that Catalpol markedly reduced the expression of PI3K, Akt and eNOS levels in renal IRI group. Suppressing of the PI3K/Akt-eNOS and the TNF-alpha, IL-1beta, IL-6 and IL-10 activities was involved in the protective effect of Catalpol on renal IRI. Collectively, Catalpol protected renal IRI via inhibiting PI3K/Akt-eNOS signaling and inflammatory responses.